Clinical Trial Update: Avonex 15 Year Long Term Follow-up Study

View source ↗

Summary

This document provides a long-term (15-year) follow-up update for Avonex (interferon beta-1a) in multiple sclerosis, with the trial status listed as completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis

Drugs mentioned

• Avonex (Interferon beta-1a)

Snippet

Sponsor: Biogen | Conditions: Multiple Sclerosis | Status: COMPLETED